Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. (Nasdaq: INTS) is a late-stage clinical biotechnology company focused on proprietary, immune-based intratumoral cancer therapies. News about Intensity centers on the clinical development of its lead investigational product candidate, INT230-6, corporate milestones, capital raises, and interactions with regulators and the Nasdaq Capital Market.
Company press releases frequently highlight progress in key clinical programs. These include the Phase 3 INVINCIBLE-3 study in specific soft tissue sarcoma subtypes, where INT230-6 is tested as second- or third-line monotherapy against standard-of-care drugs, and the Phase 2 INVINCIBLE-4 study in presurgical triple-negative breast cancer, which evaluates INT230-6 followed by standard-of-care immunochemotherapy versus standard of care alone with pathological complete response as the primary endpoint. Updates have covered enrollment status, dosing regimen adjustments, early safety observations, and notable findings such as a pathological complete response in the first evaluated patient in the INT230-6 cohort of INVINCIBLE-4.
News flow also includes scientific and medical communications, such as publication of the IT-01 Phase 1/2 study results in eBioMedicine, a Lancet Discovery Science journal, and presentations or posters at major oncology meetings like the San Antonio Breast Cancer Symposium. These items describe disease control rates, overall survival data, abscopal effects, immune activation, and pharmacokinetic findings for INT230-6 in advanced solid tumors.
Investors following INTS can also expect announcements on financial results, registered direct offerings, at-the-market equity sales, and updates on cash runway. Additional disclosures cover Nasdaq listing matters, including extensions to regain compliance with minimum bid price rules and stockholder votes on potential reverse stock splits. For those tracking Intensity Therapeutics, this news page provides a centralized view of clinical, scientific, financial, and regulatory developments related to the company and its intratumoral oncology pipeline.
Intensity Therapeutics (Nasdaq: INTS) reported 2025 year-end results and a corporate update on March 27, 2026. The company raised over $20 million in 2025 and held $11.9 million cash, with a runway into Q2 2027. Key clinical highlights include IT-01 publication showing a 75% disease control rate and median overall survival of 11.9 months, and INVINCIBLE-4 preliminary data showing a 71.4% pCR in INT230-6 pre-SOC patients versus 33% SOC alone. Swissmedic approved resumption of INVINCIBLE-4 enrollment on March 26, 2026.
Intensity Therapeutics (Nasdaq: INTS) announced a strengthening of its intellectual property portfolio with the issuance in December 2025 of US Patent No. 12,496,345, titled "A Method of Treating Cancer."
According to the company, this brings the portfolio to four U.S. patents with one U.S. application pending, patent protection across 41 countries, and a European patent validated in 27 countries. The company highlighted registered trademarks, know-how, and ongoing IP generation to protect its intratumoral drug‑conjugation technology and lead compound INT230‑6.
Intensity Therapeutics (Nasdaq: INTS) reported preliminary INVINCIBLE-4 presurgical TNBC results through March 2, 2026. Fourteen patients have been treated (7 per cohort) of a planned 61. Cohort A (INT230-6 + SOC) showed pCR in 5/7 (71.4%) vs 2/6 (33%) in SOC alone; one SOC patient remains unevaluated.
A protocol amendment to Swissmedic and the Swiss Ethics Committee was submitted to resume enrollment after a September 2025 pause for skin irritations; Cohort A showed 44% fewer grade 3+ AEs versus SOC.
Intensity Therapeutics (Nasdaq: INTS) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed the company met the requirement for 10 consecutive business days from February 19, 2026 through March 4, 2026, and the matter is now closed.
Intensity Therapeutics (Nasdaq: INTS) announced a 1-for-25 reverse stock split effective 4:01 p.m. ET on February 18, 2026, with post-split trading to begin February 19, 2026 under the existing ticker INTS.
The split reduces outstanding shares from ~63,346,579 to ~2,533,863, adjusts option/warrant conversion terms proportionally, preserves total authorized shares, and provides cash in lieu of fractional shares.
The company said the Reverse Split aims to raise the per-share trading price to regain compliance with Nasdaq’s minimum bid price requirement.
Saia (NASDAQ: SAIA) announced that its logistics arm LinkEx will operate as Saia Logistics, effective the week of Jan 15, 2026. The change consolidates Saia’s freight and logistics services under one brand to simplify customer experience and reflect integrated operations between the carrier’s LTL network and logistics capabilities. The announcement states this is a brand alignment only with no changes to ownership, service, pricing, contracts, or day-to-day operations; customers retain the same contacts and processes. Saia LTL Freight operates 213 terminals nationwide and the company offers a full suite of services including truckload, expedited, warehousing, final mile, international, and integrated logistics.
Intensity Therapeutics (Nasdaq: INTS) reviewed 2025 progress and outlined 2026 priorities focused on clinical development and capital discipline. Key 2025 highlights include a peer-reviewed publication reporting a 75% disease control rate and median overall survival of 11.9 months (and 21.3 months in a sarcoma subset), Phase 2 INVINCIBLE-4 safety observations with 50% fewer grade 3+ adverse events versus neoadjuvant chemo in early data, and initiation of a protocol amendment to revise dosing.
The company raised over $20 million in 2025, extending operating runway into Q2 2027, paused Phase 3 INVINCIBLE-3 enrollment after 21 patients due to funding, and plans to seek additional capital and partner discussions in 2026.
Intensity Therapeutics (Nasdaq: INTS) will present two posters at the 2025 San Antonio Breast Cancer Symposium on Dec 12 and Dec 11, 2025 describing early clinical observations and a potential Phase 3 design for INT230-6 in triple negative breast cancer (TNBC).
Key facts: INVINCIBLE-4 is a randomized presurgical Phase 2 trial (NCT06358573) activated in 2024 with 14 patients treated (7 per cohort). Through Nov 10, there were 9 grade ≥3 events in the INT230-6 plus SOC cohort vs 20 in SOC alone. Protocols are being modified to a single, lower-volume dose to address tumor necrosis observed after two doses. A Phase 3 concept may compare INT230-6+SOC, SOC, and INT230-6+SOC without anthracycline.
Intensity Therapeutics (Nasdaq: INTS) was granted a 180-calendar-day extension by Nasdaq to regain compliance with the exchange's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).
The initial 180-day period expired on December 3, 2025; the new compliance deadline is June 1, 2026. To regain compliance the company must maintain a closing bid of at least $1.00 per share for ten consecutive business days on or before June 1, 2026. The notification does not affect listing or trading, and shares will continue to trade on the Nasdaq Capital Market under the symbol INTS. The company said it will monitor the closing bid and take actions as needed to cure the deficiency before the end of the extension period.
Intensity Therapeutics (Nasdaq: INTS) announced two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX, taking place December 9–12, 2025.
Presentation 1: "Accelerating an Anthracycline-Free Future" — poster #801 (PS4-10-15) presented by Lewis Bender on Dec 11, 2025 at 5:00 PM CT. Presentation 2: INVINCIBLE-4-SAKK 66/22 Phase II early observations on intratumoral INT230-6 — poster #1589 (PS5-01-04) presented by Andreas Müller on Dec 12, 2025 at 12:00 PM CT.
Both presentations describe clinical and early clinical observations for INT230-6 and potential anthracycline‑sparing combinations in breast cancer therapy.